Pierre Fabre Joins IQ Consortium

Pierre Fabre Medicament announced that it has joined the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ), a scientific non-profit organization bringing together 39 pharmaceutical and biotechnology companies from around the world. The aim of the consortium is to facilitate scientific and technological partnerships among its members and enable relationships to be built with international regulatory authorities such as FDA and EMA.

Being a part of the IQ Consortium's network will allow Pierre Fabre Medicament to prepare for scientific and regulatory changes in the R&D field, and to implement and shape R&D best practices, while benefitting from the experience of other members. 

Pierre Fabre's research teams will participate in many of the Consortium's committees, including those specializing in "clinical pharmacology," "drug metabolism," "drug safety," "antibody-drug conjugates," "3Rs-alternative methods," "pharmacokinetics and pharmacodynamics," and "tissue distribution imaging."

As a member of the IQ Consortium, the Pierre Fabre Group also intends to build relationships with university and public research institutes worldwide, and to expand its international network.

Source: Pierre Fabre